• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.

作者信息

Stone Richard M, Larson Richard A, Döhner Hartmut

机构信息

Dana–Farber Cancer Institute, Boston, MA

University of Chicago Medicine, Chicago, IL

出版信息

N Engl J Med. 2017 Nov 9;377(19):1903. doi: 10.1056/NEJMc1711340.

DOI:10.1056/NEJMc1711340
PMID:29117486
Abstract
摘要

相似文献

1
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.米哚妥林用于FLT3突变的急性髓系白血病
N Engl J Med. 2017 Nov 9;377(19):1903. doi: 10.1056/NEJMc1711340.
2
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.米哚妥林治疗FLT3突变的急性髓系白血病和系统性肥大细胞增多症。
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1177-1189. doi: 10.1080/17512433.2017.1387051. Epub 2017 Oct 10.
3
[Research Progress on Treating Acute Myeloid Leukemia by Midostaurin].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Dec;23(6):1780-4. doi: 10.7534/j.issn.1009-2137.2015.06.045.
4
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.米哚妥林/PKC412用于治疗新诊断的FLT3突变阳性急性髓系白血病。
Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30.
5
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
N Engl J Med. 2017 Nov 9;377(19):1901. doi: 10.1056/NEJMc1711340.
6
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.米哚妥林治疗FLT3突变的急性髓系白血病
N Engl J Med. 2017 Nov 9;377(19):1901-2. doi: 10.1056/NEJMc1711340.
7
Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.米哚妥林：一种新型靶向 FMS 样酪氨酸激酶 3 突变的口服药物治疗急性髓系白血病。
Pharmacotherapy. 2017 Dec;37(12):1586-1599. doi: 10.1002/phar.2039. Epub 2017 Nov 23.
8
Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.米哚妥林用于治疗新诊断的FLT3突变阳性的成年急性髓系白血病患者。
Drugs Today (Barc). 2017 Oct;53(10):531-543. doi: 10.1358/dot.2017.53.10.2717625.
9
Midostaurin in FLT3-mutated acute myeloid leukaemia.米哚妥林治疗FLT3突变的急性髓系白血病
Lancet Oncol. 2017 Aug;18(8):e439. doi: 10.1016/S1470-2045(17)30506-5. Epub 2017 Jun 29.
10
Midostaurin for the treatment of acute myeloid leukemia.米哚妥林治疗急性髓系白血病。
Future Oncol. 2017 Sep;13(21):1853-1871. doi: 10.2217/fon-2017-0160. Epub 2017 Jun 14.

引用本文的文献

1
Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture.粒细胞-巨噬细胞集落刺激因子联合前列腺素 E1 从 AML 患者全血和骨髓中诱导白血病来源的树突状细胞，这些细胞在混合淋巴细胞培养后介导抗白血病过程。
Int J Mol Sci. 2023 Dec 13;24(24):17436. doi: 10.3390/ijms242417436.
2
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.一项评估依尼西单抗联合或不联合阿扎胞苷治疗新诊断 IDH2 突变 AML 疗效的研究。
Blood Adv. 2024 Jan 23;8(2):429-440. doi: 10.1182/bloodadvances.2023010563.
3
Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption.
索拉非尼用于FLT3-ITD急性髓系白血病异基因造血干细胞移植后维持治疗的真实世界经验显示，与毒性相关的治疗中断率很高。
Front Oncol. 2023 Mar 15;13:1095870. doi: 10.3389/fonc.2023.1095870. eCollection 2023.
4
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.FLT3-ITD突变状态及其比例对2901例接受一线强化化疗患者的影响：一项PETHEMA注册研究
Cancers (Basel). 2022 Nov 24;14(23):5799. doi: 10.3390/cancers14235799.
5
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.柔红霉素60与柔红霉素90及伊达比星12用于急性髓系白血病诱导化疗的回顾性分析：梅奥诊所经验
Haematologica. 2022 Oct 1;107(10):2474-2479. doi: 10.3324/haematol.2022.281045.
6
Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication.激酶激活型急性髓系白血病中质子分区的调控及其治疗意义。
Leukemia. 2022 Aug;36(8):1990-2001. doi: 10.1038/s41375-022-01606-0. Epub 2022 May 27.
7
Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance.靶向急性髓系白血病中的PI3K/AKT信号传导和DNA损伤反应：增强化疗反应并克服耐药性的新型治疗策略
Cancer Drug Resist. 2021 Nov 10;4(4):984-995. doi: 10.20517/cdr.2021.76. eCollection 2021.
8
Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge.儿科急性髓系白血病的细胞遗传学：当前知识综述。
Genes (Basel). 2021 Jun 17;12(6):924. doi: 10.3390/genes12060924.
9
SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA.SIRT5 是急性髓系白血病的可靶向代谢脆弱性。
Blood Cancer Discov. 2021 May;2(3):266-287. doi: 10.1158/2643-3230.BCD-20-0168. Epub 2019 Dec 2.
10
Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia.优化新批准药物在急性髓系白血病中的应用
J Adv Pract Oncol. 2019 Nov-Dec;10(Suppl 4):9-18. doi: 10.6004/jadpro.2019.10.8.13. Epub 2019 Nov 1.